Voyager Therapeutics (VYGR) Cash from Financing Activities (2016 - 2025)
Historic Cash from Financing Activities for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $85000.0.
- Voyager Therapeutics' Cash from Financing Activities rose 50714.29% to $85000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 9889.9%. This contributed to the annual value of $114.0 million for FY2024, which is 23887.65% up from last year.
- According to the latest figures from Q3 2025, Voyager Therapeutics' Cash from Financing Activities is $85000.0, which was up 50714.29% from $513000.0 recorded in Q2 2025.
- Over the past 5 years, Voyager Therapeutics' Cash from Financing Activities peaked at $112.9 million during Q1 2024, and registered a low of $12000.0 during Q1 2022.
- In the last 5 years, Voyager Therapeutics' Cash from Financing Activities had a median value of $344000.0 in 2021 and averaged $8.3 million.
- In the last 5 years, Voyager Therapeutics' Cash from Financing Activities surged by 26078333.33% in 2023 and then tumbled by 9992.73% in 2025.
- Quarter analysis of 5 years shows Voyager Therapeutics' Cash from Financing Activities stood at $227000.0 in 2021, then rose by 21.59% to $276000.0 in 2022, then skyrocketed by 66.67% to $460000.0 in 2023, then increased by 24.78% to $574000.0 in 2024, then crashed by 85.19% to $85000.0 in 2025.
- Its last three reported values are $85000.0 in Q3 2025, $513000.0 for Q2 2025, and $82000.0 during Q1 2025.